Cost-utility analysis of tapering strategies of biologicals in rheumatoid arthritis patients in the Netherlands.
Luuk van EsveldJuul M CoxTjallingius Martijn KuijperTessa M BoschAngelique Elisabeth Adriana Maria WeelPublished in: Annals of the rheumatic diseases (2023)
Based on these analyses, the 50% tapering approach saved the highest cost per QALY lost.